| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/17/2008 | US20080090812 Pyrrolobenzodiazepine Therapeutic Agents Useful in the Treatment of Leukemias |
| 04/17/2008 | US20080090810 Thiophene compounds |
| 04/17/2008 | US20080090809 Pyrazole compounds |
| 04/17/2008 | US20080090803 Fatty alcohol drug conjugates |
| 04/17/2008 | US20080090801 2-amino-8-(trans-4-hydroxycyclohexyl)-4-methyl-7-oxo-N-1H-pyrazol-5-yl-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide; anticarcinogenic; phosphoinositide 3-kinase alpha (PI3-K alpha ) inhibitor; cell cycle regulation, proliferation, apoptosis; inhibit resistance to cytotoxic agents in cancer cells |
| 04/17/2008 | US20080090797 tert-Butyl[3-(4-phenyloxazolidin-2-on-3-yl)-4-(2-styryl)azetidin-2-on-1-yl]acetate; known as synthetic intermediates for the preparation of beta -lactam antibiotics; diuretic |
| 04/17/2008 | US20080090793 Compounds and methods for the treatment of cancer |
| 04/17/2008 | US20080090790 Pharmaceutical composition comprising a corticosteroid and a specific inhibitor of hedgehog/smoothened signaling |
| 04/17/2008 | US20080090788 Chemical Compounds |
| 04/17/2008 | US20080090785 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents |
| 04/17/2008 | US20080090782 Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs |
| 04/17/2008 | US20080090781 Formulations Containing Alkylphosphocholines Using Novel Negative Charge Carriers |
| 04/17/2008 | US20080090776 Obtained from lung cancer patients; cDNA and genomic DNA of a novel fusion polynucleotide of an EML4 gene fused with an ALK gene as kinase (EML4-ALK fusion polynucleotide variant 1); for screening a therapeutic agent for cancer, treating cancer |
| 04/17/2008 | US20080090774 Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations |
| 04/17/2008 | US20080090763 Novel gene encoding a dna repair enzyme and methods of use thereof |
| 04/17/2008 | US20080090758 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof |
| 04/17/2008 | US20080090756 Somatostatin agonists |
| 04/17/2008 | US20080090270 Neuronal binding protein for use tool in identifying modulators for prevention and treatment of nervous system disorders |
| 04/17/2008 | US20080089997 Partially Defatted Cocoa Solids Containing Conserved Amounts of Cocoa Polyphenols |
| 04/17/2008 | US20080089959 Composition and uses of galectin antagonists |
| 04/17/2008 | US20080089951 Promoting cytokine receptor or receptor tyrosine kinase degradation in cancer cells by contacting the cells with an amount of arsenic trioxide effective to down regulate a cytokine receptor therein; treatment of head and neck squamous sarcomas and multiple myelomas |
| 04/17/2008 | US20080089950 Lymphoid tissue inducers and an immunomodulatory agent; proliferative disorders, infectious diseases, cardiovascular diseases, inflammatory disorders and autoimmune disorders |
| 04/17/2008 | US20080089945 Administering a composition comprising beeswax at a concentration of 1%-20% by weight, a fatty acid-containing oil at a concentration of at least 10% by weight and a sterol compound at a concentration of at least 1% by weight |
| 04/17/2008 | US20080089941 Fucoidan compositions and methods |
| 04/17/2008 | US20080089938 Compositions and methods for polynucleotide delivery |
| 04/17/2008 | US20080089931 EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders |
| 04/17/2008 | US20080089924 Metastasis inhibitors; foods |
| 04/17/2008 | US20080089915 Use of a specific inhibitor of hedgehog/smoothened signaling on hyperpigmented skin to obtain decrease of pigmentation |
| 04/17/2008 | US20080089898 Immunotoxins directed against CD33 related surface antigens |
| 04/17/2008 | US20080089896 Bivalent SMAC mimetics and the uses thereof |
| 04/17/2008 | US20080089895 Using antisense agents specific to lymphocyte membrane protein (TIRC7) as therapeutic tools in treatment and prevention of cell proliferative, vision and ischemic heart defects; wound healing agents |
| 04/17/2008 | US20080089893 therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies; Anticancer agent |
| 04/17/2008 | US20080089888 Nucleotide sequences coding cancer/testis antigen for use in identifying modulators for prevention and treatment of cell proliferative disorders |
| 04/17/2008 | US20080089887 Members of the FC Receptor Homolog Gene Family (FcRH1-3,6) Related Reagents and Uses Thereof |
| 04/17/2008 | US20080089886 Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 04/17/2008 | US20080089885 Anti-cd20 antibodies and methods of use |
| 04/17/2008 | US20080089882 Novel Polypeptide Useful for Cancer Diagnosis and Treatment |
| 04/17/2008 | US20080089869 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
| 04/17/2008 | US20080089864 Viral sequences for targeted replication in tumor cells |
| 04/17/2008 | US20080089860 Such as pentamidine; cytokines; interferons; granulocyte/macrophage colony stimulating factor; for treatment of diseases associated with PTPase activity, immune deficiency, cancer, infections, hepatitis B, and hepatitis C |
| 04/17/2008 | CA2703466A1 Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers |
| 04/17/2008 | CA2683122A1 Therapy targeting cathepsin s |
| 04/17/2008 | CA2666249A1 Agent for preventing/treating cancer |
| 04/17/2008 | CA2666184A1 The use of a dna damaging agent and a ligand for the treatment of cancer |
| 04/17/2008 | CA2666170A1 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate |
| 04/17/2008 | CA2666130A1 Kinase inhibitors |
| 04/17/2008 | CA2666112A1 Pyrrolydine derivatives as iap inhibitors |
| 04/17/2008 | CA2665931A1 Hydrobenzamide derivatives as inhibitors of hsp90 |
| 04/17/2008 | CA2665692A1 Combination drug |
| 04/17/2008 | CA2665605A1 New isocarbostyril alkaloid derivatives |
| 04/17/2008 | CA2665127A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 04/17/2008 | CA2665068A1 Methods for treating cancer with mva |
| 04/17/2008 | CA2664826A1 Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| 04/17/2008 | CA2603132A1 Peptide inhibitors of cyclin-dependent kinase activity and uses thereof |
| 04/16/2008 | EP1912066A1 Auxiliary method for diagnosis and therapy of cancer with nucleolin |
| 04/16/2008 | EP1911837A2 FAD4, FAD5, FAD5-2, and FAD6, fatty acid desaturase family members and uses thereof |
| 04/16/2008 | EP1911754A1 Dipeptidyl peptidase inhibitors |
| 04/16/2008 | EP1911743A1 Cyclic amine compound |
| 04/16/2008 | EP1911449A1 Anti-tumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof |
| 04/16/2008 | EP1911448A2 Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
| 04/16/2008 | EP1910535A1 Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same |
| 04/16/2008 | EP1910523A1 Modulation of egfr signalling by modulation of sphingosine kinase signalling |
| 04/16/2008 | EP1910419A2 Compositions and methods for the diagnosis and treatment of tumor |
| 04/16/2008 | EP1910408A2 Bifunctional protein anchors |
| 04/16/2008 | EP1910383A1 Benzodiazepine derivatives and uses thereof in medical field |
| 04/16/2008 | EP1910380A1 Oxazolopyridine derivatives as sirtuin modulators |
| 04/16/2008 | EP1910377A2 Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds |
| 04/16/2008 | EP1910375A1 Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors |
| 04/16/2008 | EP1910370A1 A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
| 04/16/2008 | EP1910368A1 Pyrazolo[1.5-a]pyrimidin-7-yl amine derivatives as protein kinase inhibitors |
| 04/16/2008 | EP1910358A2 Heterocyclic janus kinase 3 inhibitors |
| 04/16/2008 | EP1910347A2 Macrocylic inhibitors of hepatitis c virus |
| 04/16/2008 | EP1910344A2 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 04/16/2008 | EP1910342A1 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| 04/16/2008 | EP1910339A2 Azepane- or azocane-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 04/16/2008 | EP1910336A1 Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 04/16/2008 | EP1910326A1 Antitumoral compounds |
| 04/16/2008 | EP1910312A1 Quadratic acid ii derivatives |
| 04/16/2008 | EP1910301A2 Cycloalkane-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 04/16/2008 | EP1910300A2 Prodrugs of pyrazoline compounds, their preparation and use as medicaments |
| 04/16/2008 | EP1910288A1 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof |
| 04/16/2008 | EP1910275A2 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field |
| 04/16/2008 | EP1910270A2 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field |
| 04/16/2008 | EP1909910A1 Benzimidazole derivatives as sirtuin modulators |
| 04/16/2008 | EP1909854A1 Method for treating cancer |
| 04/16/2008 | EP1909849A2 Use of mutant herpes simplex virus-2 for cancer therapy |
| 04/16/2008 | EP1909827A2 The modulation of immunity and ceacam1 activity |
| 04/16/2008 | EP1909821A2 Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders |
| 04/16/2008 | EP1909812A2 Small compounds that correct protein misfolding and uses thereof |
| 04/16/2008 | EP1909811A2 Gene regulation |
| 04/16/2008 | EP1909804A1 Glucosamine and derivatives thereof useful as tg inhibitors |
| 04/16/2008 | EP1909803A2 Guanosine-rich oligonucleotides as agents for inducing cell death in eukaryotic cells |
| 04/16/2008 | EP1909800A1 Acylglycerophospholipids for treating symptoms concomitant with cancer |
| 04/16/2008 | EP1909794A2 Combination of organic compounds |
| 04/16/2008 | EP1909785A2 Use of progesterone receptor modulators |
| 04/16/2008 | EP1909778A1 Sensitization of immune system against haptenized melanoma antigens |
| 04/16/2008 | EP1909600A1 Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases |
| 04/16/2008 | EP1799690B1 Thiazolyl-dihydro indazoles |
| 04/16/2008 | EP1581471B1 Cyclopentenone derivatives for cancer therapy |
| 04/16/2008 | EP1423382B1 Pyrazole-derived kinase inhibitors and uses thereof |